Studie - Respiratory and Pulmonary System Respiratory Tract Infections

Life Science Analytics', 'Respiratory and Pulmonary System Respiratory Tract Infections ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.

UPCOMING PATENT EXPIRES BY THERAPY AREA

Respiratory Tract Infections Pipeline Overview

--% of Projects (By Phase of Development)

--No. of Projects by Phase of Development

--Marketed Products Vs. Pipeline Products

Company Overview - Pipeline Projects

--Company Overview - Pipeline Projects



--Top Companies in late stage Respiratory Tract Infections Projects

--Bayer Ag

--Nektar Therapeutics

--OctoPlus N.V.

--Replidyne Inc

--Shionogi & Co., Ltd.

--Zeria Pharmaceutical Co., Ltd.



--Top Companies in early stage Respiratory Tract Infections Projects

--Arpida Ltd.

--Aridis Pharmaceuticals, LLC

--GlaxoSmithKline plc

--AstraZeneca Plc

--Nanotherapeutics, Inc.

--Kenta Biotech Ltd.

--Optimer Pharmaceuticals, Inc.

--Novexel

--Phynova Group PLC

--Oscient Pharmaceuticals Corp

--Vaxart, Inc.

--Sanofi-Aventis



Pipeline Revenue

--Pipeline Revenue

Full Pipeline View

--Pre Clinical Pipeline View

--Phase I Pipeline View

--Phase II Pipeline View

--Phase III Pipeline View

--Pending Approval Pipeline View

--On the Market Pipeline View

--Discovery/Development Pipeline View

• Commercial Insight: Asthma/COPD in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies - Guatemala
• Asthma Therapy Area Pipeline Report
• Bronchitis Therapy Area Pipeline Report
• Bronchospasm Therapy Area Pipeline Report
• Asthma - Drug Pipeline Analysis and Market Forecasts to 2016
• Pipeline Insight: Asthma/COPD - Simplified treatments to split the market
• Asthma and COPD Market Forecast
• Commercial Insight: Asthma & COPD - On the verge of generic entry
• Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
• Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers?
• Respiratory and Pulmonary System Asthma
• Respiratory and Pulmonary System Bronchitis
• Respiratory and Pulmonary System Bronchospasm
• Respiratory and Pulmonary System Chronic Obstructive Pulmonary Disease
• Respiratory and Pulmonary System Cough
• Respiratory and Pulmonary System Cystic Fibrosis
• Respiratory and Pulmonary System Nasal congestion
• Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma